3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
35
Breast Neoplasms
27
Prostatic Neoplasms
22
Stomach Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
12
Neoplasms
10
Lung Neoplasms
10
Urinary Bladder Neoplasms
8
Head and Neck Neoplasms
8
Triple Negative Breast Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Squamous Cell
6
Non-Muscle Invasive Bladder Neoplasms
5
Nasopharyngeal Carcinoma
5
Carcinoma, Transitional Cell
5
Adenocarcinoma
5
Oropharyngeal Neoplasms
4
Sarcoma
3
Prostatic Neoplasms, Castration-Resistant
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Metastatic Castration-resistant Prostate Cancer
3
HER2-positive Breast Cancer
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Vaccinia
2
Recurrence
2
Peritoneal Neoplasms
2
Metastatic Castration-Resistant Prostate Cancer
2
Interventions
atezolizumab
3
fludarabine
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
Pemetrexed
2
Nivolumab
2
Cisplatin
2
spartalizumab
1
repotrectinib
1
pertuzumab
1
lutetium Lu 177 dotatate
1
gilteritinib
1
enzalutamide
1
durvalumab
1
copper dotatate CU-64
1
cemiplimab
1
Trastuzumab
1
Sodium Chloride
1
Radiotherapy
1
Radiosurgery
1
Mitomycin
1
Lutetium-177
1
Lutetium
1
Injections
1
Idarubicin
1
HuMax-IL8
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms by Histologic Type
×
Docetaxel
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled